Repligen CFO sells 530 shares under trading plan

Repligen Corp Chief Financial Officer Jason K. Garland reported selling 530 shares of Common Stock on July 16, 2026 at $150.0000 per share, in a transaction described as a sale in an open market or private transaction.

Rhea-AI Filing Summary

Repligen Corp Chief Financial Officer Jason K. Garland reported selling 530 shares of Common Stock on July 16, 2026 at $150.0000 per share, in a transaction described as a sale in an open market or private transaction. The sale was effected under a Rule 10b5-1 trading plan adopted on December 8, 2025, and he now directly holds 18,829 shares.

Insider Trade Summary 10b5-1

Net Seller: 530 shares

Net Sell 1 txn

Insider Garland Jason K

Role CFO

Sold 530 shs ($80K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1	530	$150.00	$80K

Holdings After Transaction: Common Stock — 18,829 shares (Direct)

Footnotes (1)

1. F1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 8, 2025.

Key Figures

Shares sold: 530 shares Sale price: $150.0000 per share Shares owned after sale: 18,829 shares +2 more

5 metrics

Shares sold 530 shares Common Stock sale reported for July 16, 2026

Sale price $150.0000 per share Price per share for Common Stock sale

Shares owned after sale 18,829 shares Total Common Stock directly owned following transaction

Net shares sold 530 shares Net sell shares from transactionSummary

10b5-1 plan adoption date December 8, 2025 Date the reporting person adopted the Rule 10b5-1 trading plan

Key Terms

Rule 10b5-1 trading plan, Form 4, open market or private transaction

3 terms

Rule 10b5-1 trading plan regulatory

"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

Form 4 regulatory

"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

open market or private transaction financial

"Transaction code description: Sale in open market or private transaction"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Repligen (RGEN) report for CFO Jason Garland?

Repligen CFO Jason K. Garland reported a sale of 530 shares of Common Stock at $150.0000 per share on July 16, 2026. The transaction was coded as a sale in an open market or private transaction and executed under a pre-arranged Rule 10b5-1 trading plan.

How many Repligen (RGEN) shares did the CFO sell and at what price?

CFO Jason K. Garland sold 530 shares of Repligen Common Stock at $150.0000 per share. This single reported transaction on July 16, 2026 was classified as a sale in an open market or private transaction under a Rule 10b5-1 trading plan.

When did the Repligen (RGEN) CFO’s stock sale occur and under what plan?

The sale took place on July 16, 2026 and was executed under a Rule 10b5-1 trading plan. According to the disclosure, Jason K. Garland adopted this trading plan on December 8, 2025, providing for pre-arranged transactions in Repligen stock.

How many Repligen (RGEN) shares does CFO Jason Garland hold after this Form 4 sale?

After the reported transaction, Jason K. Garland directly holds 18,829 shares of Repligen Common Stock. This post-transaction holding figure reflects his remaining direct ownership following the sale of 530 shares on July 16, 2026 under the trading plan.

Was the Repligen (RGEN) CFO’s share sale made under a Rule 10b5-1 plan?

Yes. The filing states that the sales were effected pursuant to a Rule 10b5-1 trading plan. The reporting person adopted this plan on December 8, 2025, and the Form 4 indicates the Rule 10b5-1 plan affirmation checkbox as applicable for this transaction.

Is the Repligen (RGEN) Form 4 transaction a buy or a sell by the insider?

The reported transaction is a sale of Common Stock by the Repligen CFO. It involves 530 shares disposed of at $150.0000 per share, leaving him with 18,829 shares directly owned after the transaction, according to the Form 4 disclosure and summary data.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/17/2026 - 04:40 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Garland Jason K

(Last) (First) (Middle)

C/O REPLIGEN CORPORATION

41 SEYON ST., BLDG 1, STE 100

(Street)

WALTHAM MASSACHUSETTS 02453

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
REPLIGEN CORP [ RGEN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CFO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/16/2026		S(1)		530	D	$150	18,829	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 8, 2025.

	/s/ Jennifer Carmichael (Attorney in Fact)	07/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)